Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01833897 · ClinicalTrials.gov registry record · Phase 4
NMDA Antagonists in Bipolar Depression
A Phase 4 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
NCT01833897 is a Phase 4 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 8 participants.
The verdict
NCT01833897, a Phase 4 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether ketamine and D-cycloserine can be safely and effectively used for the treatment of depression. The investigators hypothesize that ketamine will serve as a rapid acting and safe antidepressant in patients with bipolar depression, and furthermore, that D-cycloserine will serve as an effective therapy following ketamine treatment.
Interventions
- DRUG Ketamine
- DRUG Standard of Care
- DRUG D-cycloserine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-03 |
| Est. Completion | 2016-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01833897
The ClinicalTrials.gov registry entry for NCT01833897 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ketamine is the first listed.
NCT01833897 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01833897 about?
NCT01833897 is a clinical study titled "NMDA Antagonists in Bipolar Depression". The purpose of this study is to test whether ketamine and D-cycloserine can be safely and effectively used for the treatment of depression. The investigators hypothesize that ketamine will serve as a rapid acting and safe antidepressant in patients with bipolar depression, and furthermore, that D-cy...
What is the current status of trial NCT01833897?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2013-03. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01833897?
The interventions under investigation include: Ketamine (DRUG), Standard of Care (DRUG), D-cycloserine (DRUG).
Who is sponsoring clinical trial NCT01833897?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.